SMARCA2 and cancer: While PROTACs like AU15330 provide high selectivity over ATPase subunits of SWI/SNF complex, they may not provide a therapeutic advantage in cancers where BRG1 and ARID1A are tumor suppressors, as BRG1/BRM degradation may further compromise their tumor-suppressive ability and jeopardize the cancer cells by developing other mutations due to deregulated genomic instability.